Great Novel Therapeutics Biotech & Medicals (TPEX:7427)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
40.10
-0.80 (-1.96%)
Apr 29, 2026, 1:58 PM CST
2.43%
Market Cap 1.72B
Revenue (ttm) 1.21M
Net Income (ttm) -97.47M
Shares Out 42.95M
EPS (ttm) -2.26
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 352,527
Average Volume 767,400
Open 40.75
Previous Close 40.90
Day's Range 39.65 - 40.95
52-Week Range 29.25 - 57.00
Beta 0.08
RSI 62.27
Earnings Date Aug 12, 2026

About TPEX:7427

Great Novel Therapeutics Biotech & Medicals engages in the development of drugs for the treatment of advanced and refractory cancers. The company develops drugs for cancer immunotherapy, including tumor microenvironment regulators, epigenetic immunoactivators, and immune-regulating multi-kinase inhibitors. The company was formerly known as GNT Biotech & Medicals Corporation. Great Novel Therapeutics Biotech & Medicals was founded in 2013 and is based in Taipei, Taiwan. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2013
Employees 15
Stock Exchange Taipei Exchange
Ticker Symbol 7427
Full Company Profile

Financial Performance

In 2025, TPEX:7427's revenue was 1.21 million, a decrease of -28.49% compared to the previous year's 1.69 million. Losses were -97.47 million, -7.10% less than in 2024.

Financial Statements

News

There is no news available yet.